PTN

Palatin Technologies Inc

4.77

Oct 27 • 3:59 PM ET -0.05 (-1.04%)

4.65

Aftermarket • 5:32 PM ET -0.12 (-2.52%)

Healthcare Biotechnology USA Nano NASD

Peers: LPCN RYTM ALDX DARE SKYE MTVA KALA ALT OKYO ENTX

| Held by: VXF IWC

Scroll to Statements

Index	-
Market Cap	8.50M
Enterprise Value	1.23M
Income	-8.38M
Sales	13.19M
Book/sh	3.76
Cash/sh	4.20
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	25
IPO	Oct 28, 1993

P/E	-
Forward P/E	-
PEG	-
P/S	0.64
P/B	1.27
P/C	1.13
P/FCF	-
EV/EBITDA	-
EV/Sales	0.09
Quick Ratio	4.61
Current Ratio	4.61
Debt/Eq	0.03
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-0.08
EPS next Y	-2.13
EPS next Q	-0.42
EPS this Y	26.24%
EPS next Y	2.60%
EPS next 5Y	3.08%
EPS past 3/5Y	70.06% 55.89%
Sales past 3/5Y	39.53% -
EPS Y/Y TTM	101.28%
Sales Y/Y TTM	3581.22%
EPS Q/Q	53.65%
Sales Q/Q	-
Earnings	Sep 28 BMO
EPS/Sales Surpr.	7.50% -79.97%

Insider Own	5.58%
Insider Trans	0.00%
Inst Own	49.63%
Inst Trans	0.39%
ROA	-142.11%
ROE	-877.53%
ROIC	-124.08%
Gross Margin	-
Oper. Margin	-65.74%
Profit Margin	-63.54%
SMA20	-35.20%
SMA50	-49.60%
SMA200	-66.43%
Trades

Shs Outstand	1.78M
Shs Float	1.68M
Short Float	19.78%
Short Ratio	4.94
Short Interest	0.33M
52W High	31.00 -84.61%
52W Low	4.58 4.15%
Volatility	11.66% 11.41%
ATR (14)	0.86
RSI (14)	19.49
Beta	0.72
Rel Volume	0.50
Avg Volume	67.23K
Volume	33,298

Perf Week	-13.59%
Perf Month	-50.21%
Perf Quarter	-40.97%
Perf Half Y	-77.51%
Perf YTD	-68.99%
Perf Year	-17.06%
Perf 3Y	-95.13%
Perf 5Y	-99.09%
Perf 10Y	-99.26%
Recom	1.00
Target Price	53.50
Prev Close	4.82
Price	4.77
Change %	-1.04%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-25	Initiated	Laidlaw	Buy	$60
Dec-03-25	Initiated	Alliance Global Partners	Buy	$50

Oct-21-26 01:16PM	Big Pharma's Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN) (FinanceWire)
Sep-28-26 07:30AM	Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update (PR Newswire) -5.10%
Sep-15-26 08:00AM	GLP-1s Transformed Obesity. Billions Are Now Moving Into Rare Diseases That Require a Different Approach. (FinanceWire) -18.11%
Aug-06-26 09:40AM	StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It (Newsfile Corp.)
Jul-22-26 10:34AM	What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin's Rare-Obesity Opportunity (FinanceWire) -5.45%
04:00PM	Loading…
May-18-26 04:00PM	Palatin to Begin Trading on Nasdaq Stock Exchange (PR Newswire) +5.76% -6.36%
May-13-26 07:03PM	Palatin Technologies Inc (PTN) Q3 2026 Earnings Call Highlights: Strategic Advances Amidst ... (GuruFocus.com) -16.01% -9.82%
07:30AM	Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
Feb-17-26 06:00PM	Palatin Technologies Inc (PTN) Q2 2026 Earnings Call Highlights: Strategic Advances Amid Rising ... (GuruFocus.com) +10.01%
07:30AM	Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update (PR Newswire)
Nov-13-25 07:30AM	Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update (PR Newswire)
Nov-12-25 12:15PM	Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option (PR Newswire) +29.43%

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WILLS STEPHEN T	Executive VP and CFO/COO	Dec 24 '25	Sale	16.74	565	9,461	63,488	Dec 29 04:30 PM
WILLS STEPHEN T	Director	Dec 24 '25	Proposed Sale	16.74	565	9,461		Dec 29 10:42 AM

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Princeton, NJ.

Co-FounderDr. Carl Spana Ph.D.

MSTMr. Stephen T. Wills C.P.A.

Vice President of Investor RelationsBurns McClellan

Chief Legal OfficerMr. Stephen A. Slusher Esq.

M.S.Mr. James E. Hattersley B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTN

Palatin Technologies Inc

Upgrade your Finviz experience